CN209270373U - A kind of sustained release drug carrier of radium-shine molding release hole - Google Patents
A kind of sustained release drug carrier of radium-shine molding release hole Download PDFInfo
- Publication number
- CN209270373U CN209270373U CN201821884914.9U CN201821884914U CN209270373U CN 209270373 U CN209270373 U CN 209270373U CN 201821884914 U CN201821884914 U CN 201821884914U CN 209270373 U CN209270373 U CN 209270373U
- Authority
- CN
- China
- Prior art keywords
- drug
- drug coating
- radium
- insoluble
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a kind of sustained release drug carriers of radium-shine molding release hole, belong to medicament slow release control technology field.A kind of sustained release drug carrier of radium-shine molding release hole, including outer drug coating, it further include main ingredient object and ancillary drug, the main ingredient object and ancillary drug are arranged inside outer drug coating, the main ingredient object includes drug coating and insoluble interior drug coating in solubility, is provided with radium-shine molding release hole on the insoluble interior drug coating；Drug coating, which keeps out gastric juice corrosion, in the solubility of main ingredient object can reach the small intestine of user, and the slow releasing pharmaceutical that drug coating is filled in the small enteral dissolution of user, insoluble interior drug coating in solubility is released by radium-shine molding release hole；Using drug coating and insoluble interior drug coating three-layer protection layer in outer drug coating, solubility, enable the different location release diffusion in user's body stage by stage of ancillary drug and slow releasing pharmaceutical.
Description
Technical field
The utility model relates to medicament slow release control technology fields, more specifically to a kind of radium-shine molding release hole
Sustained release drug carrier.
Background technique
Slow releasing pharmaceutical is also known as sustained release preparation, refers to that slowly non-constant velocity is released as required after taking orally in regulation dissolution medium
The preparation for putting drug, compared with corresponding ordinary preparation, administration frequency is reduced, and can be dramatically increased the compliance of patient or be reduced medicine
The side effect of object.Drug release belongs to 1 step velocity process in general sustained release preparation.Existing slow releasing pharmaceutical exists and cannot take stage by stage
In user's body the problem of different location release diffusion.
Utility model content
1. technical problems to be solved
It is existing in the prior art cannot stage by stage in user's body different location release diffusion aiming at the problem that, this reality
With a kind of novel sustained release drug carrier for being designed to provide radium-shine molding release hole, it, which can solve, to take stage by stage
In person's body the problem of different location release diffusion.
2. technical solution
To solve the above problems, the utility model adopts the following technical scheme.
A kind of sustained release drug carrier of radium-shine molding release hole, including outer drug coating further includes main ingredient object and ancillary drug,
The main ingredient object and ancillary drug are arranged inside outer drug coating, and the main ingredient object includes drug coating in solubility
With insoluble interior drug coating, radium-shine molding release hole is provided on the insoluble interior drug coating；
The insoluble interior drug coating is arranged in solubility on the inside of drug coating, the insoluble interior drug packet
Slow releasing pharmaceutical is filled in clothing.
Preferably, it is assisted between drug coating filled with drug absorption in the insoluble interior drug coating and solubility
Agent.
Preferably, soluble diaphragm is fixedly connected on the inside of the radium-shine molding release hole.
It preferably, further include reverse osmosis membrane, the insoluble interior drug coating end portion is the insoluble diaphragm of elasticity,
The insoluble diaphragm of elasticity is fixedly connected with reverse osmosis membrane both ends, between the insoluble diaphragm of elasticity and reverse osmosis membrane
Filling helps releaser.
Preferably, co-penetrant is filled in the reverse osmosis membrane and solubility between drug coating.
3. beneficial effect
Compared with the prior art, utility model has the advantages that
(1) the utility model is by being provided with main ingredient object and ancillary drug, and after user takes, outer drug coating protects medicine
Object reaches stomach, and gastric juice dissolves outer drug coating, and ancillary drug is acted in user's generation, drug packet in the solubility of main ingredient object
Clothing, which keeps out gastric juice corrosion, can reach the small intestine of user, and drug coating is in the small enteral dissolution of user in solubility, no
The slow releasing pharmaceutical filled in drug coating in dissolubility is released by radium-shine molding release hole；Using outer drug coating, solvable
Drug coating and insoluble interior drug coating three-layer protection layer in property, enable ancillary drug and slow releasing pharmaceutical taking stage by stage
Different location release diffusion in person's body；
(2) the utility model is additionally provided with drug absorption adjuvant, and drug coating is molten in the small enteral of user in solubility
Xie Hou, the drug absorption adjuvant release filled in dissolubility between drug coating and insoluble interior drug coating, drug absorption are auxiliary
Auxiliary agent accelerates small intestine absorbent slow release drug, in main ingredient object before the discharge of small enteral, small intestine is enable to absorb more slow releasing pharmaceuticals,
Improve the service efficiency of drug；The utility model is additionally provided with soluble diaphragm, drug absorption adjuvant may directly with it is slow
Drug effect is released, soluble diaphragm can separate drug absorption adjuvant with slow releasing pharmaceutical, prevent main ingredient object from entering user
Drug absorption adjuvant and slow releasing pharmaceutical act on before small intestine, slow releasing pharmaceutical drug effect are influenced, when main ingredient object enters user's small intestine
Afterwards, drug coating is discharged in the small enteral dissolution of user, drug absorption adjuvant in solubility, soluble diaphragm dissolution, sustained release
Drug is released by radium-shine molding release hole, and drug absorption adjuvant accelerates small intestine absorbent slow release drug, improves drug
Service efficiency；
(3) the utility model is additionally provided with reverse osmosis membrane, and drug coating is after the small enteral dissolution of user in solubility, clothes
The enteral water of user penetrates reverse osmosis membrane, helps releaser water swelling that slow releasing pharmaceutical is accelerated to discharge by radium-shine molding release hole
Out, so that more slow releasing pharmaceuticals is can be transferred through radium-shine molding release hole before the discharge of small enteral in main ingredient object and release, from
And improve the service efficiency of drug；The utility model is additionally provided with co-penetrant, and drug coating is in user's small intestine in solubility
After interior dissolution, co-penetrant is mixed with small enteral liquid, increases the rate that water penetrates reverse osmosis membrane, further to improve drug
Service efficiency.
Detailed description of the invention
Fig. 1 is the positive structure diagram of the utility model；
Fig. 2 is the main ingredient object structural schematic diagram of the utility model.
Figure label explanation:
It is 1 outer drug coating, 2 main ingredient objects, 3 ancillary drugs, drug coating in 4 solubilities, 5 drug absorption adjuvants, 6 insoluble
Property in drug coating, 7 radium-shine molding release holes, 8 slow releasing pharmaceuticals, 9 help releaser, the 10 insoluble diaphragms of elasticity, 11 reverse osmosis membranes,
12 co-penetrants, 13 soluble diaphragms.
Specific embodiment
The following is a combination of the drawings in the embodiments of the present utility model；The technical scheme in the embodiment of the utility model is carried out
Clearly and completely describe；Obviously；The described embodiments are only a part of the embodiments of the utility model；Rather than whole
Embodiment.Based on the embodiments of the present invention；Those of ordinary skill in the art are without making creative work
Every other embodiment obtained；It fall within the protection scope of the utility model.
Embodiment 1:
A kind of sustained release drug carrier of radium-shine molding release hole, including outer drug coating 1, further include main ingredient object 2 and adjuvant
Object 3, main ingredient object 2 and ancillary drug 3 are arranged inside outer drug coating 1, and main ingredient object 2 includes 4 He of drug coating in solubility
Insoluble interior drug coating 6 is provided with radium-shine molding release hole 7 on insoluble interior drug coating 6；
4 inside of drug coating, filling in insoluble interior drug coating 6 is arranged in solubility in insoluble interior drug coating 6
There is slow releasing pharmaceutical 8.
The utility model is by being provided with main ingredient object 2 and ancillary drug 3, and after user takes, outer drug coating 1 protects medicine
Object reaches stomach, and gastric juice dissolves outer drug coating 1, and ancillary drug 3 is acted in user's generation, medicine in the solubility of main ingredient object 2
Gastric juice corrosion is kept out in object coating 4 can reach the small intestine of user, and drug coating 4 is molten in the small enteral of user in solubility
Solution, the interior slow releasing pharmaceutical 8 filled of insoluble interior drug coating 6 are released by radium-shine molding release hole 7；Using outer drug packet
6 three-layer protection layer of drug coating 4 and insoluble interior drug coating in clothing 1, solubility, enables ancillary drug 3 and slow releasing pharmaceutical 8
The different location release diffusion in user's body stage by stage.
Embodiment 2:
1 basis in conjunction with the embodiments, the difference is that: insoluble interior drug coating 6 and drug coating 4 in solubility
Between be filled with drug absorption adjuvant 5.
Soluble diaphragm 13 is fixedly connected on the inside of radium-shine molding release hole 7.
The utility model is additionally provided with drug absorption adjuvant 5, and drug coating 4 is in the small enteral dissolution of user in solubility
Afterwards, the drug absorption adjuvant 5 filled between drug coating 4 and insoluble interior drug coating 6 in dissolubility discharges, and drug absorption is auxiliary
Auxiliary agent 5 accelerates small intestine absorbent slow release drug 8, in main ingredient object 2 before the discharge of small enteral, small intestine is enable to absorb more slow releasing medicinals
Object 8 improves the service efficiency of drug；The utility model is additionally provided with soluble diaphragm 13, and drug absorption adjuvant 5 may be straight
It connects and is acted on slow releasing pharmaceutical 8, soluble diaphragm 13 can separate drug absorption adjuvant 5 and slow releasing pharmaceutical 8, prevent main ingredient object
2 enter drug absorption adjuvant 5 and the effect of slow releasing pharmaceutical 8 before user's small intestine, 8 drug effect of slow releasing pharmaceutical are influenced, when main ingredient object 2
Into after user's small intestine, in the small enteral dissolution of user, drug absorption adjuvant 5 discharges drug coating 4, solvable in solubility
Property diaphragm 13 dissolve, slow releasing pharmaceutical 8 is released by radium-shine molding release hole 7, and drug absorption adjuvant 5 accelerates small intestinal absorption
Slow releasing pharmaceutical 8 improves the service efficiency of drug.
Embodiment 3:
1 basis in conjunction with the embodiments, the difference is that: it further include reverse osmosis membrane 11, under insoluble interior drug coating 6
End is divided into the insoluble diaphragm 10 of elasticity, and the insoluble diaphragm 10 of elasticity is fixedly connected with 11 both ends of reverse osmosis membrane, and elasticity is insoluble
Filling helps releaser 9 between diaphragm 10 and reverse osmosis membrane 11.
Co-penetrant 12 is filled in reverse osmosis membrane 11 and solubility between drug coating 4.
The utility model is additionally provided with reverse osmosis membrane 11, and drug coating 4 is after the small enteral dissolution of user in solubility, clothes
The enteral water of user penetrates reverse osmosis membrane 11, helps 9 water swelling of releaser that slow releasing pharmaceutical 8 is accelerated to pass through radium-shine molding release hole
7 release, and in main ingredient object 2 before the discharge of small enteral, so that more slow releasing pharmaceuticals 8 is can be transferred through radium-shine molding release hole 7 and release
It releases, to improve the service efficiency of drug；The utility model is additionally provided with co-penetrant 12, drug coating 4 in solubility
After the small enteral dissolution of user, co-penetrant 12 is mixed with small enteral liquid, increases the rate that water penetrates reverse osmosis membrane 11, into
The service efficiency of the raising drug of one step.
It is described above；The only preferable specific embodiment of the utility model；But the protection scope of the utility model is not
It is confined to this；Anyone skilled in the art is within the technical scope disclosed by the utility model；It is practical according to this
Novel technical solution and its improvement design is subject to equivalent substitution or change；It should all cover in the protection scope of the utility model
It is interior.In addition, one word of " comprising " is not excluded for other elements or step, "one" word before the component is not excluded for including " multiple " be somebody's turn to do
Element.The multiple multiple elements stated in claim to a product can also by an element by software or hardware come real
It is existing.The first, the second equal words are used to indicate names, and are not indicated any particular order.
Claims (5)
1. a kind of sustained release drug carrier of radium-shine molding release hole, including outer drug coating (1), it is characterised in that: further include main ingredient
Object (2) and ancillary drug (3), the main ingredient object (2) and ancillary drug (3) setting are internal in outer drug coating (1), described
Main ingredient object (2) includes drug coating in solubility (4) and insoluble interior drug coating (6), the insoluble interior drug packet
Radium-shine molding release hole (7) is provided on clothing (6)；
The insoluble interior drug coating (6) is arranged in solubility on the inside of drug coating (4), the insoluble interior drug
It is coated in (6) and is filled with slow releasing pharmaceutical (8).
2. the sustained release drug carrier of the radium-shine molding release hole of one kind according to claim 1, it is characterised in that: described is insoluble
Property in be filled with drug absorption adjuvant (5) between drug coating (4) in drug coating (6) and solubility.
3. the sustained release drug carrier of the radium-shine molding release hole of one kind according to claim 2, it is characterised in that: described is radium-shine
Soluble diaphragm (13) are fixedly connected on the inside of molding release hole (7).
4. the sustained release drug carrier of the radium-shine molding release hole of one kind according to claim 1, it is characterised in that: further include reverse osmosis
Permeable membrane (11), insoluble interior drug coating (6) end portion are the insoluble diaphragm (10) of elasticity, and the elasticity is insoluble
Property diaphragm (10) be fixedly connected with reverse osmosis membrane (11) both ends, the insoluble diaphragm (10) of described elasticity and reverse osmosis membrane (11) it
Between filling help releaser (9).
5. the sustained release drug carrier of the radium-shine molding release hole of one kind according to claim 4, it is characterised in that: the reverse osmosis
Co-penetrant (12) are filled between drug coating (4) in permeable membrane (11) and solubility.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201821884914.9U CN209270373U (en) | 2018-11-16 | 2018-11-16 | A kind of sustained release drug carrier of radium-shine molding release hole |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201821884914.9U CN209270373U (en) | 2018-11-16 | 2018-11-16 | A kind of sustained release drug carrier of radium-shine molding release hole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN209270373U true CN209270373U (en) | 2019-08-20 |
Family
ID=67601413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201821884914.9U Expired - Fee Related CN209270373U (en) | 2018-11-16 | 2018-11-16 | A kind of sustained release drug carrier of radium-shine molding release hole |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN209270373U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111387222A (en) * | 2019-09-12 | 2020-07-10 | 浙江海洋大学 | Spindle water flea eliminating agent |
-
2018
- 2018-11-16 CN CN201821884914.9U patent/CN209270373U/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111387222A (en) * | 2019-09-12 | 2020-07-10 | 浙江海洋大学 | Spindle water flea eliminating agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880002511A (en) | Oral Therapy System Showing Systemic Action | |
| CN101502491B (en) | Dirithromycin enteric-coated formulation | |
| CN1692906B (en) | Single-chamber, double-layered osmosis pump control-release system with holes on two sides | |
| EP0616802B1 (en) | Oral preparation for release in lower digestive tracts | |
| CN105663096B (en) | A kind of Wo Nuolazan oral quick-dissolving film preparation and preparation method thereof | |
| BRPI0710914A2 (en) | dosage form and method for the treatment of nicotine addiction, addiction and suppression, in particular for use in smoking cessation therapy | |
| CN209270373U (en) | A kind of sustained release drug carrier of radium-shine molding release hole | |
| CN101524544A (en) | Composite gel film agent | |
| CN101152158A (en) | Method of producing double-layer core permeation pump patch of medicament | |
| CN108030770A (en) | Controllable dry suspensoid agent of drug release containing drug-resin complex and preparation method thereof | |
| CN1977972B (en) | Anti tumour drug oral colon targeting preparation and its preparing method | |
| CN101214229A (en) | Colon-targeted orally-administered preparation with double-layer coatings and preparation thereof | |
| CN102871984A (en) | Phenylephrine hydrochloride oral instant membrane and preparation method thereof | |
| CN102552171B (en) | A kind of andrographolide colon-targeted micropellet and preparation method thereof | |
| CN103550191A (en) | Ibuprofen and its salt painless microneedle transdermal patch and its preparation method | |
| CN103284974B (en) | Benzene ring nonyl ester double-layer osmotic pump controlled-release tablet and preparation method thereof | |
| CN106727445A (en) | A kind of Dapagliflozin pelliculae pro cavo oris and preparation method thereof | |
| CN105902483A (en) | Preparation method of temperature-sensitive material suitable for transdermal delivery | |
| CN106074440B (en) | A kind of capsule and preparation method thereof | |
| CN101869544A (en) | Ambroxol hydrochloride controlled release suspension and preparation method thereof | |
| CN106491556A (en) | A kind of stable montelukast sodium enteric-coated pellet | |
| CN214018532U (en) | Capsule for gentamicin monoclonal antibody | |
| CN108143722A (en) | A kind of paroxetine hydrochloride enteric-coated sustained-release tablet and preparation method thereof | |
| CN102600103B (en) | Capsule shells of a kind of colon positioning release and preparation method thereof | |
| CN108057029A (en) | A kind of Zaltoprofen fast release micropill preparation, preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190820 Termination date: 20201116 |